Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-3028 in Patients With Castration Resistant Prostate Cancer (CRPC)

NCT07285694 is registered in ClinicalTrials.gov with Arsenal Biosciences, Inc. as lead sponsor.

NCT NCT07285694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07285694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-3028 in Patients With Castration Resistant Prostate Cancer (CRPC)
Lead sponsor
Arsenal Biosciences, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 9, 2026
Completion date
May 31, 2031
Enrollment
190 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer (mcrpc)